NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings results on Thursday, November, 21st. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.56 by $0.12. The biotechnology company earned $51.30 million during the quarter, compared to analyst estimates of $55.95 million. Enanta Pharmaceuticals had a net margin of 22.60% and a return on equity of 10.46%. The business's revenue for the quarter was down 23.7% compared to the same quarter last year. During the same period last year, the company earned $1.30 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

Enanta Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 brokers have issued 1 year target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 87.0% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Media headlines about ENTA stock have trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 2,440,000 shares, an increase of 7.0% from the November 28th total of 2,280,000 shares. Based on an average daily trading volume, of 197,600 shares, the days-to-cover ratio is presently 12.3 days. Currently, 14.1% of the company's shares are short sold. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Myokardia (MYOK) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.38%), New York State Teachers Retirement System (0.24%), Virginia Retirement Systems ET AL (0.06%), Strs Ohio (0.06%), State of Alaska Department of Revenue (0.06%) and Arizona State Retirement System (0.05%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Arizona State Retirement System, Louisiana State Employees Retirement System, Valeo Financial Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, New York State Teachers Retirement System, Virginia Retirement Systems ET AL, Strs Ohio, Wedge Capital Management L L P NC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $54.19.

Enanta Pharmaceuticals has a market capitalization of $1.07 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]